Research graph
References from Hospitalization outcomes in adults with type 2 diabetes mellitus treated with once-weekly insulin efsitora versus once-daily basal insulins: A post hoc analysis of the QWINT-1 to −4 randomized trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study
10.1016/s2213-8587(15)00362-9 · 2016 · External reference
10.2337/dci18-0007
10.2337/dci18-0007 · External reference
Proportions and trends of adult hospitalizations with diabetes, United States, 2000-2018
10.1016/j.diabres.2022.109862 · 2022 · External reference
10.2337/dc19-0653
10.2337/dc19-0653 · External reference
Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes
10.1001/jamanetworkopen.2019.19099 · 2020 · External reference
Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy
10.1056/nejmoa2502796 · 2025 · External reference
Efficacy and safety of once‐weekly versus once‐daily basal insulin analogues in the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis
10.1111/dom.15259 · 2023 · External reference
Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis
10.1007/s11892-026-01628-3 · 2026 · External reference
Insights on hospitalisations from the phase 3a ONWARDS 1-6 trials of once-weekly insulin icodec
10.1007/s13300-025-01745-4 · 2025 · External reference
Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes
10.1080/14656566.2026.2667324 · 2026 · External reference
Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme
10.1111/dom.15604 · 2024 · External reference
Unresolved reference
External reference
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes
10.1111/dom.14956 · 2023 · External reference
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial
10.1016/s0140-6736(25)01044-x · 2025 · External reference
Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment
10.1056/nejmoa2403953 · 2024 · External reference
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
10.1016/s0140-6736(25)01069-4 · 2025 · External reference
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records
10.1016/s2213-8587(21)00288-6 · 2022 · External reference
